 | Up a level |
Journal Article
Eberhardt, W. E. E., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J. and Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063. Oncol. Res. Treat., 40. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262
Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Reck, M., Vicente, D., Ciuleanu, T., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Wolf, J., Antonia, S. J., Nakagawa, K., Selvaggi, G., Baudelet, C., Chang, H. and Spigel, D. R. (2018). Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Ann. Oncol., 29. S. 43 - 44. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041